# Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis

> **NCT02520908** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 98 (actual)

## Conditions studied

- Epidermotropic T-cell Lymphomas

## Interventions

- **PROCEDURE:** HSCT
- **OTHER:** Standard Care

## Key facts

- **NCT ID:** NCT02520908
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09-23
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520908, "Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02520908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*